TrialJournal of comparative effectiveness research2022
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients.
Craig M McDonald et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
31 papers cite it
this paperpooled ittrialcites it